VBI Vaccines Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St

March 15, 2023

VBI Vaccines (NASDAQ:VBIV) Full Year 2022 Results

Key Financial Results

Net loss: US$113.3m (loss widened by 62% from FY 2021).
US$0.44 loss per share (further deteriorated from US$0.27 loss in FY 2021).

VBIV Products In Clinical Trials

Phase I: 5.
Phase II: 1.

earnings-and-revenue-history — NasdaqCM:VBIV Earnings and Revenue History March 15th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

VBI Vaccines Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 8.2%. Earnings per share (EPS) missed analyst estimates by 31%.

Looking ahead, revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 5.1% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with VBI Vaccines (at least 1 which doesn't sit too well with us), and understanding them should be part of your investment process.

If you're looking to trade VBI Vaccines, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.